Full Brain Solution is reportedly the only artificial intelligence (AI)-enabled software that facilitates detection of medium vessel occlusions (MeVOs) as well as anterior and posterior large vessel occlusions (LVOs) on computed tomography (CT) exams.
Ischemic strokes reportedly account for 87 percent of the 795,000 annual strokes that occur in the United States, according to the Centers for Disease Control and Prevention (CDC). Researchers have estimated that medium vessel occlusions (MeVOs) cause between 25 to 40 percent of ischemic strokes and 24 to 46 percent of ischemic strokes are due to large vessel occlusions (LVOs).
With these statistics in mind, Aidoc has launched the Full Brain Solution, an AI-powered software that helps diagnose MeVOs and LVOs on computed tomography (CT) scans.
"AI has shown remarkable success in enhancing workflow for patients with anterior LVOs, nearly halving the time to treatment. However, this is just the beginning. With Aidoc’s Full Brain Solution, we can now broaden these advancements to benefit a significantly larger patient population, leading to improved care and ultimately better outcomes,” noted Brian Mason, M.D., an associate professor of neuroendovascular surgery at the University of Illinois Champaign.
In addition to aiding the diagnosis of acute ischemic strokes, Aidoc said the Full Brain Solution utilizes AI image-based detection and natural language processing to enhance diagnosis and facilitate subsequent care for patients with brain aneurysms as well as subdural and intracerebral hemorrhages.
(Editor’s note: For related content, see "RapidAI Gets FDA Nod for AI Assessment of Non-Contrast CT for Acute Stroke Triage” and “FDA Clears AI-Powered Stroke Imaging Tool for Non-Contrast CT.”)
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.